These findings suggest that pharmacological inhibition of miR-221-222 binding to p53-upregulated apoptosis regulator mRNA represents a potential therapeutic strategy to overcome dexamethasone resistance in MM patients. This evidence concerns the gene TP53 and Miyoshi myopathy.